APLTライブシグナル | Getagraph.comで利益を最大化

買う 107823 min ago

@ $2.66

発行日: 15 2月 2024 @ 04:44

リターン: 65.04%

前回のシグナル: 2月 15 - 03:41

前回のシグナル: 売る

リターン: -3.45 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:46):

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications...

Stats
本日の出来高	124 309
平均出来高	1.83M
時価総額	501.52M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-0.0700 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.09
ATR14	$0.00800 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-12	Hooks Corwin Dale	Buy	300 000	Common Stock
2024-04-12	Hooks Corwin Dale	Buy	0
2024-03-14	Shendelman Shoshana	Sell	318 573	Common Stock
2024-03-14	Perfetti Riccardo	Sell	110 804	Common Stock
2024-03-14	Hansard Adam	Sell	48 871	Common Stock

INSIDER POWER
41.30
Last 97 transactions
Buy: 24 985 894 \| Sell: 4 549 161

ボリューム相関

長: 0.00 (neutral)

短: 0.64 (weak)

Signal:(51.626) Neutral

Applied Therapeutics Inc 相関

10 最も正の相関
NISN	0.932
EYPT	0.926
SEAC	0.906
CYCN	0.901
SCR	0.891
ADMP	0.889
ICON	0.889
WORX	0.889
ACLX	0.889
LEGN	0.886

10 最も負の相関
CHDN	-0.91
REYN	-0.884
SCOR	-0.882
VTRU	-0.881
DCRC	-0.877
SGLB	-0.872
ALGM	-0.866
ENLV	-0.863
MTEX	-0.863
DCGO	-0.862

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Applied Therapeutics Inc 相関 - 通貨/商品

0.62
( weak )

0.66
( moderate )

0.00
( neutral )

0.66
( moderate )

0.30
( neutral )

-0.57
( weak negative )

Applied Therapeutics Inc 財務諸表

Annual	2023
収益:	$9.99M
総利益:	$9.64M (96.47 %)
EPS:	$-1.420

FY	2023
収益:	$9.99M
総利益:	$9.64M (96.47 %)
EPS:	$-1.420

FY	2022
収益:	$0
総利益:	$-441 000 (0.00 %)
EPS:	$-2.16

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-4.12

Financial Reports:

No articles found.

Applied Therapeutics Inc

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.